Rockwell Medical (NASDAQ: RMTI) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk & Volatility

Rockwell Medical has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Institutional & Insider Ownership

21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 95.4% of Supernus Pharmaceuticals shares are held by institutional investors. 15.9% of Rockwell Medical shares are held by insiders. Comparatively, 6.7% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Rockwell Medical and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rockwell Medical -39.68% -42.22% -27.15%
Supernus Pharmaceuticals 41.10% 30.73% 19.48%

Earnings & Valuation

This table compares Rockwell Medical and Supernus Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Rockwell Medical $54.04 million 6.37 -$21.07 million ($0.42) -15.83
Supernus Pharmaceuticals $252.59 million 8.98 $82.36 million $1.95 22.95

Supernus Pharmaceuticals has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Rockwell Medical and Supernus Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rockwell Medical 1 0 1 1 2.67
Supernus Pharmaceuticals 0 2 4 0 2.67

Rockwell Medical currently has a consensus target price of $9.33, suggesting a potential upside of 40.35%. Supernus Pharmaceuticals has a consensus target price of $48.33, suggesting a potential upside of 8.01%. Given Rockwell Medical’s higher probable upside, equities research analysts plainly believe Rockwell Medical is more favorable than Supernus Pharmaceuticals.

Summary

Supernus Pharmaceuticals beats Rockwell Medical on 9 of the 13 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.